Sixfold Bioscience

About Sixfold Bioscience

Sixfold Bioscience develops Mergo®, a platform that utilizes AI to enhance the delivery mechanisms for RNA therapies. This technology addresses the challenge of effectively transporting RNA molecules to target cells, improving therapeutic efficacy and patient outcomes.

<problem> Effective delivery of RNA therapies to target cells remains a significant challenge, limiting their therapeutic potential and patient outcomes. Traditional delivery methods often struggle with stability, specificity, and efficient cellular uptake. </problem> <solution> Sixfold Bioscience has developed Mergo®, an AI-driven platform designed to enhance the delivery of RNA therapies. Mergo® addresses the limitations of existing delivery mechanisms by improving the stability, targeting, and cellular uptake of RNA molecules. This technology aims to increase the efficacy of RNA therapeutics, leading to better patient outcomes. By leveraging AI, Mergo® optimizes the delivery process, ensuring that RNA therapies reach their intended targets with greater precision and efficiency. </solution> <features> - AI-driven platform for optimizing RNA delivery mechanisms - Enhanced stability of RNA molecules during transit - Improved targeting of specific cells and tissues - Increased cellular uptake of RNA therapies </features> <target_audience> The primary target audience includes pharmaceutical companies and research institutions focused on developing and improving RNA-based therapeutics. </target_audience>

What does Sixfold Bioscience do?

Sixfold Bioscience develops Mergo®, a platform that utilizes AI to enhance the delivery mechanisms for RNA therapies. This technology addresses the challenge of effectively transporting RNA molecules to target cells, improving therapeutic efficacy and patient outcomes.

Where is Sixfold Bioscience located?

Sixfold Bioscience is based in London, United Kingdom.

When was Sixfold Bioscience founded?

Sixfold Bioscience was founded in 2018.

How much funding has Sixfold Bioscience raised?

Sixfold Bioscience has raised $10.6M.

Location
London, United Kingdom
Founded
2018
Funding
$10.6M
Employees
15 employees
Investors
Bossa InvestY CombinatorCantosFundamental VenturesLombardstreetPicampusThe Venture Collective

Sixfold Bioscience

10
Relative Traction Score based on online presence metrics compared to companies in the same age group.

Executive Summary

Sixfold Bioscience develops Mergo®, a platform that utilizes AI to enhance the delivery mechanisms for RNA therapies. This technology addresses the challenge of effectively transporting RNA molecules to target cells, improving therapeutic efficacy and patient outcomes.

sixfold.bio5K+
Founded 2018 – London, United Kingdom

Funding

No specific funding rounds found.

Total Funding

$10.6M

Backed by

Y CombinatorBossa InvestCantosEuropean CommissionFundamental Ventures…

Team (15+)

Søren Ottosen

Søren Ottosen

Rajiv Kapoor

Rajiv Kapoor

Company Description

Problem

Effective delivery of RNA therapies to target cells remains a significant challenge, limiting their therapeutic potential and patient outcomes. Traditional delivery methods often struggle with stability, specificity, and efficient cellular uptake.

Solution

Sixfold Bioscience has developed Mergo®, an AI-driven platform designed to enhance the delivery of RNA therapies. Mergo® addresses the limitations of existing delivery mechanisms by improving the stability, targeting, and cellular uptake of RNA molecules. This technology aims to increase the efficacy of RNA therapeutics, leading to better patient outcomes. By leveraging AI, Mergo® optimizes the delivery process, ensuring that RNA therapies reach their intended targets with greater precision and efficiency.

Features

AI-driven platform for optimizing RNA delivery mechanisms

Enhanced stability of RNA molecules during transit

Improved targeting of specific cells and tissues

Increased cellular uptake of RNA therapies

Target Audience

The primary target audience includes pharmaceutical companies and research institutions focused on developing and improving RNA-based therapeutics.

Sources:

1
This profile is AI-generated from web data and may contain inaccuracies. Want to correct or remove an entry? Owners can claim edits via their company email domain, and signed-in users can submit sourced suggestions.